Patient info Search Menu

Omeflex Special emulsion for infusion – patient leaflet, side effects, dosage

Updated:

Patient leaflet - Omeflex Special emulsion for infusion

1. What Omeflex special is and what it is used for

Omeflex special contains fluids and substances called amino acids, electrolytes and fatty acids that are essential for the body to grow or to recover. It also contains calories in the form of carbohydrates and fats. Omeflex special is given to adults, adolescents and children older than two years.

You are given Omeflex special when you are unable to eat food normally. There are many situations when this might be the case, for example when you are recovering from surgery, injuries, or burns, or when you are unable to absorb food from your stomach and gut.

2. What you need to know before you use Omeflex special

Do not use Omeflex special

  • if you are allergic to any of the active substances, to egg, peanut, soybean or fish or to any of the other ingredients of this medicine (listed in section 6).
  • This medicine must not be given to newborn infants, infants and toddlers under two years old.

Also, do not use Omeflex special if you suffer from any of the following: • life-threatening blood circulation problems such as those that can occur if you are in a state of collapse or shock

  • heart attack or stroke
  • severely impaired blood clotting function, bleeding risk (severe coagulopathy, aggravating haemorrhagic diatheses)
  • blocking of blood vessels by blood clots or fat (embolism) • severe liver failure
  • impaired bile flow (intrahepatic cholestasis)
  • severe kidney failure in the absence of kidney replacement therapy • disturbances of your body salt composition
  • fluid deficit or excess water in your body
  • water on your lungs (pulmonary oedema)
  • severe heart failure
  • certain metabolic disorders such as

    • too much lipid (fat) in the blood
    • inborn errors of amino acid metabolism
    • abnormally high blood sugar level that needs more than 6 units of insulin per hour to be controlled
    • abnormalities of metabolism that may occur after operations or injuries
    • coma of unknown origin
    • insufficient supply of oxygen to tissues
    • abnormally high acid level in the blood.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before using Omeflex special. Please inform your doctor if:

  • you have heart, liver or kidney problems
  • you suffer from certain types of metabolic disorders such as diabetes, abnormal blood fat values and disorders of your body fluid and salt composition or your acid-base balance

You will be monitored closely to detect early signs of an allergic reaction (such as fever, shivering, rash, or shortness of breath) when you receive this medicine.

Further monitoring and tests such as various examinations of blood samples will be applied to make sure that your body handles the administered foodstuffs properly.

Your healthcare professional will also take measures to ensure that your body’s fluid and electrolyte requirements are met. In addition to Omeflex special you will receive further nutrients (foodstuffs) in order to fully cover your requirements.

Children

This medicine must not be given to newborn infants, infants and toddlers under two years old.

Other medicines and Omeflex special

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.

Omeflex special can interact with some other medicines. Please tell your doctor, pharmacist or nurse if you are taking or receiving any of the following:

  • insulin
  • heparin
  • medicines that prevent undesirable blood clotting such as warfarin or other coumarin derivatives
  • medicines to promote urine flow (diuretics)
  • medicines to treat high blood pressure or heart problems (ACE-inhibitors and angiotensin-II-receptor antagonists)
  • medicines used in organ transplants such as ciclosporin and tacrolimus • medicines to treat inflammation (corticosteroids)
  • hormone preparations that affect your fluid balance (adrenocorticotropic hormone [ACTH]).

    Pregnancy and breast-feeding

    If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. If you are pregnant you will receive this medicine only if the doctor or pharmacist considers it absolutely necessary for your recovery. There is no data available about the use of Omeflex special in pregnant women.

    Breast-feeding is not recommended for mothers on parenteral nutrition.

    Driving and using machines

    This medicine is normally given to immobile patients, e.g. in a hospital or clinic which would exclude driving or using machines. However, the medicine itself has no effect on the ability to drive and use machines.

    Omeflex special special contains sodium

    This medicine contains 1.244 mg sodium (main component of cooking/ table salt) in each ml. This is equivalent to 0.062% of the recommended maximum daily dietary intake of sodium for an adult.

    The maximum recommended daily dose of this medicinal product contains 3048 mg sodium (found in table salt). This is equivalent to 152% of the adult recommended maximum daily dietary intake for sodium. Talk to your doctor or pharmacist if you need one or more bags daily for a prolonged period, especially if you have been advised to follow a low salt (sodium) diet.

3. How to use Omeflex special

This medicine is administered by intravenous infusion (drip), that is, through a small tube directly into a vein. This medicine will be administered through one of your large (central) veins only. The recommended duration of infusion for a parenteral nutrition bag is maximum 24 h. Your doctor or pharmacist will decide how much of this medicine you need and for how long you will require treatment with this medicine.

Use in children

This medicine must not be given to newborn infants, infants and toddlers under 2 years old.

Your doctor will decide how much of this medicine your child needs and for how long your child will require treatment with this medicine.

If you use more Omeflex special than you should

If you have received too much of this medicine you may suffer from a so-called ‘overload syndrome’ and the following symptoms: • fluid excess and electrolyte disorders

  • water on your lungs (pulmonary oedema)
  • loss of amino acids through the urine and disturbed amino acid balance • vomiting, feeling sick
  • shivering
  • high blood sugar level
  • glucose in the urine
  • fluid deficit
  • blood much more concentrated than normal (hyperosmolality) • impairment or loss of consciousness due to extremely high blood sugar • enlargement of the liver (hepatomegaly) with or without jaundice (icterus)
  • enlargement of the spleen (splenomegaly)
  • fat deposition in the inner organs
  • abnormal values of liver function tests
  • reduction of red blood cell count (anaemia)
  • reduction of white blood cell count (leucopenia)
  • reduction of blood platelet count (thrombocytopenia) • increase of immature red blood cells (reticulocytosis)
  • rupture of blood cells (haemolysis)
  • bleeding or a tendency to bleeding
  • impairment of blood coagulation (as can be seen by changes of bleeding time, coagulation time, prothrombin time etc.)
  • fever
  • high blood fat levels
  • loss of consciousness

If any of these symptoms occur, the infusion must be stopped immediately. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects may be serious. If any of the following side effects occur, tell your doctor immediately, he will stop giving you this medicine:

Rare (may affect up to 1 in 1,000 people):

  • allergic reactions, for example skin reactions, shortness of breath, swelling of the lips, mouth and throat, difficulty breathing

Other side effects include:

Uncommon (may affect up to 1 in 100 people):

  • feeling sick, vomiting, loss of appetite

Rare (may affect up to 1 in 1,000 people):

  • increased tendency for your blood to clot
  • bluish discolouration of the skin
  • shortness of breath
  • headache
  • flushing

B|BRAUN

Package leaflet: Information for the user

B. Braun Melsungen AG · 34209 Melsungen, Germany

Omeflex® special emulsion for infusion

The following information is intended for healthcare professionals only: Parenteral nutrition products should be visually inspected for damage, discolouration and emulsion instability before use.

Do not use bags which are damaged. Overwrap, primary bag and the peel seams between the chambers should be intact. Only use if the amino acid and glucose solutions are clear and colourless up to straw-coloured and the lipid emulsion is homogenous with milky white appearance. Do not use if the solutions contain particulate matter.

After mixing the three chambers, do not use if the emulsion shows discolouration or signs of phase separation (oil drops, oil layer). Stop the infusion immediately in case of discolouration of the emulsion or signs of phase separation.

Before opening the overwrap, check the colour of the oxygen indicator (see Figure A). Do not use if the oxygen indicator turned pink. Use only if the oxygen indicator is yellow.

Preparation of the mixed emulsion

Strict adherence to aseptic

handling principles must be

complied with.

To open: Tear overwrap starting

from the tear notches (Fig. 1).

Remove the bag from its protective

overwrap. Discard overwrap, oxygen

indicator and oxygen absorber.

Visually inspect the primary bag for leaks. Leaky bags must be discarded, since the sterility cannot be guaranteed.

Mixing of the bag and addition of

additives

To open and mix the chambers

sequentially, roll the bag with both

hands, starting first by opening the

peel seam that separates the top

chamber (glucose) and the bottom

chamber (amino acids) (Fig. 2).

B|BRAUN

✃

Then continue applying pressure so that the peel seam separating the middle chamber (lipids) and the bottom chamber opens (Fig. 3).

3

After all chambers are mixed and following the removal of the aluminium seal (Fig. 3A), one can add compatible additives via the medication port (Fig. 4). Mix the contents thoroughly (Fig. 5) and visually inspect the mixture (Fig. 6). The mixture is a milky white homogenous oil-in-water emulsion. There should be no signs of emulsion phase separation.

Black (8% – 100%)

Dimension: 210 x 594 mm

LLD-Spec.: L94M

Production code: 8879

LIFE_N___3CB___GB___0179 0179/12632920/0724

3CB, GIF

Production site: Melsungen (LIFE N)

V-0013

Black (8% – 100%)

Dimension: 210 x 594 mm

LLD-Spec.: L94M

Production code: 8879

LIFE_N___3CB___GB___0179____ZV0525 0179/12632920/0525

3CB, GIF

Production site: Melsungen (LIFE N)

V-0013

0179/12632920/0525 in 1000 ml in 625 ml in 1250 ml in 1875 ml

Energy in the form

of lipids [kJ (kcal)]

1590

(380)

(240)

1990

(475)

2985 (715) Energy in the form

of carbohydrates [kJ (kcal)]

2415

(575)

1510

(360)

3015

(720)

4520 (1080) Energy in the form

of amino acids [kJ (kcal)]

(225)

(140)

1170

(280)

1755 (420) Non-protein energy

[kJ (kcal)]

4005

(955)

2505

(600)

5005

(1195)

7510 (1795) Total energy

[kJ (kcal)]

4945

(1180)

3090

(740)

6175

(1475)

9260 (2215)

Osmolality [mOsm/kg] 2115

Theoretical osmolarity [mOsm/l] 1545

pH 5.0 - 6.0

The other ingredients are citric acid monohydrate (for pH adjustment), egg phospholipids for injection, glycerol, sodium oleate, all-rac-alpha-tocopherol, sodium hydroxide (for pH adjustment) and water for injections.

What Omeflex special looks like and contents of the pack

The ready-to-use product is an emulsion for infusion, i.e. it is administered through a small tube into a vein.

Omeflex special is supplied in flexible multichamber bags containing:

  • 625 ml (250 ml of amino acids solution + 125 ml of fat emulsion + 250 ml of glucose solution)
  • 1250 ml (500 ml of amino acids solution + 250 ml of fat emulsion + 500 ml of glucose solution)
  • 1875 ml (750 ml of amino acids solution + 375 ml of fat emulsion + 750 ml of glucose solution)

Figure A Figure B

Figure A: The multichamber bag is packed in a protective overwrap. An oxygen absorber and an oxygen indicator are placed between the bag and the overwrap; the oxygen absorber sachet is made of inert material and contains iron hydroxide.

Figure B: The top chamber contains a glucose solution, the middle chamber contains a fat emulsion, and the bottom chamber contains an amino acid solution.

The glucose and the amino acid solutions are clear and colourless up to straw-coloured. The fat emulsion is milky white.

The top chamber and the middle chamber can be connected with the bottom chamber by opening the intermediate seams.

The different container sizes are presented in cartons containing five bags. Pack sizes: 5 x 625 ml, 5 x 1250 ml and 5 x 1875 ml

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

B. Braun Melsungen AG

Carl-Braun-Straße 1 Postal address:

34212 Melsungen, Germany 34209 Melsungen, Germany Phone: +49-5661-71-0

Fax: +49-5661-71-4567

This medicine is authorised in the Member States of the European Economic Area and in the United Kingdom (GB and NI) under the following names:

Austria Nutriflex Omega special B.Braun Emulsion zur Infusion Belgium Nutriflex Omega special 56 g/l Amino + 144g/l G, emulsie voor infusie

Bulgaria Nutriflex Omega 56/144 special emulsion for infusion Croatia Nutriflex Omega 56/144 specijal emulzija za infuziju Czech Republic Nutriflex Omega special 56/144

Denmark Nutriflex Omega Special

Estonia Nutriflex Omega 56/144 infusiooniemulsioon Finland Nutriflex Omega 56/144/40 infuusioneste, emulsio France REANUTRIFLEX OMEGA E, émulsion pour perfusion Germany NuTRIflex Omega special novo Emulsion zur Infusion Greece Nutriflex Omega 56/144 special

Ireland Omeflex special emulsion for infusion Italy Omegaflex AA56/G144 emulsione per infusione Latvia Nutriflex Omega 56/144 emulsija infūzijām Lithuania Nutriflex Omega 56/144 infuzinė emulsija Luxembourg NuTRIflex Omega special novo Emulsion zur Infusion Netherlands Nutriflex Omega special, 56 g/l Amino + 144 g/l G, emulsie voor infusie

Norway Nutriflex Omega Special infusjonsvæske, emulsjon Poland Omegaflex special

Portugal Nutriflex Omega 56/144 S emulsão para perfusão Romania NuTRIflex Omega Special novo, emulsie perfuzabilă Slovakia Nutriflex Omega special 56/144

Slovenia Nutriflex Omega special 56/144 emulzija za infundiranje

Spain Omegaflex especial emulsión para perfusión Sweden Nutriflex Omega 56/144/40 infusionsvätska, emulsion United Kingdom

(GB and NI) Omeflex special emulsion for infusion

This leaflet was last revised in 07/2026

  • reddening of skin (erythema)
  • sweating
  • chills
  • feeling cold
  • high body temperature
  • drowsiness
  • pain in the chest, back, bones or lumbar region
  • decrease or increase in blood pressure

Very rare (may affect up to 1 in 10,000 people):

  • abnormally high blood fat or blood sugar values
  • high levels of acidic substances in your blood
  • Too much lipid can lead to fat overload syndrome, for more information on this please see under the heading “If you use more Omeflex special than you should” in section 3. Symptoms normally disappear when the infusion is stopped.

Not known (frequency cannot be estimated from the available data): • reduction of white blood cell count (leucopenia)

  • reduction of blood platelet count (thrombocytopenia) • impaired bile flow (cholestasis)

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.

You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Omeflex special

Keep this medicine out of the sight and reach of children. Do not store above 25 °C.

Do not freeze. If accidentally frozen, discard the bag.

Do not use this medicine after the expiry date which is stated on the label. The expiry date refers to the last date of that month.

Keep the bag in the protective overwrap in order to protect from light.

6. Contents of the pack and other information

What Omeflex special contains

The active substances in the ready-for-use mixture are: from the top chamber

(glucose solution)

in 1000 ml in 625 ml in 1250 ml in 1875 ml

Glucose monohydrate 158.4 g 99.00 g 198.0 g 297.0 g equivalent to glucose 144.0 g 90.00 g 180.0 g 270.0 g Sodium dihydrogen

phosphate dihydrate

2.496 g 1.560 g 3.120 g 4.680 g

Zinc acetate dihydrate 7.024 mg 4.390 mg 8.780 mg 13.17 mg

from the middle chamber

(fat emulsion)

in 1000 ml in 625 ml in 1250 ml in 1875 ml

Medium-chain

triglycerides

20.00 g 12.50 g 25.00 g 37.50 g

Soya-bean oil, refined 16.00 g 10.00 g 20.00 g 30.00 g Omega-3-acid

triglycerides

4.000 g 2.500 g 5.000 g 7.500 g

from the bottom chamber

(amino acid solution)

in 1000 ml in 625 ml in 1250 ml in 1875 ml

Isoleucine 3.284 g 2.053 g 4.105 g 6.158 g Leucine 4.384 g 2.740 g 5.480 g 8.220 g Lysine hydrochloride 3.980 g 2.488 g 4.975 g 7.463 g equivalent to lysine 3.186 g 1.991 g 3.982 g 5.973 g Methionine 2.736 g 1.710 g 3.420 g 5.130 g Phenylalanine 4.916 g 3.073 g 6.145 g 9.218 g Threonine 2.540 g 1.588 g 3.175 g 4.763 g Tryptophan 0.800 g 0.500 g 1.000 g 1.500 g Valine 3.604 g 2.253 g 4.505 g 6.758 g Arginine 3.780 g 2.363 g 4.725 g 7.088 g Histidine hydrochloride

monohydrate

2.368 g 1.480 g 2.960 g 4.440 g

equivalent to histidine 1.753 g 1.095 g 2.191 g 3.286 g Alanine 6.792 g 4.245 g 8.490 g 12.73 g Aspartic acid 2.100 g 1.313 g 2.625 g 3.938 g Glutamic acid 4.908 g 3.068 g 6.135 g 9.203 g Glycine 2.312 g 1.445 g 2.890 g 4.335 g Proline 4.760 g 2.975 g 5.950 g 8.925 g Serine 4.200 g 2.625 g 5.250 g 7.875 g Sodium hydroxide 1.171 g 0.732 g 1.464 g 2.196 g Sodium chloride 0.378 g 0.237 g 0.473 g 0.710 g Sodium acetate trihydrate 0.250 g 0.157 g 0.313 g 0.470 g Potassium acetate 3.689 g 2.306 g 4.611 g 6.917 g Magnesium acetate

tetrahydrate

0.910 g 0.569 g 1.137 g 1.706 g

Calcium chloride dihydrate 0.623 g 0.390 g 0.779 g 1.169 g

in 1000 ml in 625 ml in 1250 ml in 1875 ml

Amino acid content [g] 56.0 35.0 70.1 105.1 Nitrogen content [g] 8 5 10 15 Carbohydrate content [g] 144 90 180 270 Lipid content [g] 40 25 50 75

Electrolytes [mmol] in 1000 ml in 625 ml in 1250 ml in 1875 ml

Sodium 53.6 33.5 67 100.5 Potassium 37.6 23.5 47 70.5 Magnesium 4.2 2.65 5.3 7.95 Calcium 4.2 2.65 5.3 7.95 Zinc 0.03 0.02 0.04 0.06 Chloride 48 30 60 90 Acetate 48 30 60 90 Phosphate 16 10 20 30

B. Braun Melsungen AG

34209 Melsungen, Germany

B|BRAUN

B. Braun Melsungen AG

34209 Melsungen, Germany

B|BRAUN

✃

Omeflex special can be mixed with the following additives up to the below specified upper concentration limits or maximum amount of additives after supplementation. The resulting admixtures are stable for 7 days between +2 °C to +8 °C plus 2 days at 25 °C.

  • Electrolytes: take account of the electrolytes already present in the bag; stability has been demonstrated up to a total quantity of 200 mmol/l of sodium + potassium (sum), 9.6 mmol/l of magnesium and 6.4 mmol/l of calcium in the ternary mixture.
  • Phosphate: stability has been demonstrated up to a maximum concentration of 20 mmol/l for inorganic phosphate or up to a maximum concentration of 30 mmol/l for organic phosphate (not both at the same time).
  • Alanyl-Glutamin up to 24 g/l.
  • Trace elements and vitamins: stability has been demonstrated with commercially available multi-trace elements and multi-vitamins (e.g. Tracutil, Cernevit) up to the standard dosage recommended by the respective manufacturer of the micronutrient.

Detailed information about the above mentioned additives and the corresponding shelf life of such admixtures can be provided on demand by the manufacturer.

Preparation for infusion

The emulsion should always be brought to room temperature prior to infusion.

Remove the aluminium foil from the infusion port (Fig. 7) and attach the infusion set (Fig. 8). Use a non-vented infusion set or close the air vent when using a vented set. Hang the bag on an infusion stand (Fig. 9) and carry out infusion using the standard technique.

For single use only. Container and unused residues must be discarded after use.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Do not reconnect partially used containers.

The medicinal product must be administered via a lipid-permeable filter with a pore size of 1.2 µm.

Shelf life after removing the protective overwrap and after mixing of the contents of the bag

Chemical and physicochemical in-use stability of the mixture of amino acids, glucose and fat was demonstrated for 7 days at 2-8 °C and additional 2 days at 25 °C.

Shelf life after admixture of compatible additives

From a microbiological point of view, the product should be used immediately after admixture of additives. If not used immediately after admixture of additives, in-use storage times and conditions prior to use are the responsibility of the user. After first opening (spiking of the infusion port)

The emulsion is to be used immediately after opening of the container. Omeflex special must not be mixed with other medicinal products for which compatibility has not been documented.

Omeflex special should not be given simultaneously with blood in the same infusion set due to the risk of pseudoagglutination.

0179/12632920/0525

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 03551/0144

Last revision stated in the text: July 2026 · MHRA data as of 13 October 2026

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Omeflex Special emulsion for infusion

What these facts mean

Active substances? L-Histidine hydrochloride monohydrate, L-Tryptophan, Omega-3-acid triglycerides, L-Serine, L-Phenylalanine, Isoleucine, Glycine, Soya oil, Sodium hydroxide, L-Methionine, Sodium chloride, MEDIUM CHAIN TRIGLYCERIDES, L-Aspartic acid, Potassium acetate, L-Proline, Arginine, L-Threonine, Alanine, Magnesium acetate tetrahydrate, Calcium chloride dihydrate, Zinc acetate dihydrate, Glucose monohydrate, Sodium acetate trihydrate, Valine, L-Lysine monohydrochloride, Sodium dihydrogen phosphate dihydrate, Leucine, L-Glutamic acid
Pharmaceutical form? Amino acids and glucose solutions: clear, colourless up to straw-coloured solutions
Fat emulsion: oil-in-water emulsion, milky white
Excipients? Citric acid monohydrate (for pH adjustment), Glycerol, Egg phospholipids for injection, Sodium oleate, Sodium hydroxide (for pH adjustment), all-rac-alpha-tocopherol, Water for injections
Shelf life? Unopened
2 years
After removing the protective overwrap and after mixing of the contents of the bag Chemical and physicochemical in-use stability of the mixture of amino acids, glucose and fat was demonstrated for 7 days at 2-8 °C and additional 2 days at 25 °C.
After admixture of compatible additives
From a microbiological point of view, the product should be used immediately after admixture of additives. If not used immediately after admixture of additives, in-use storage times and conditions prior to use are the responsibility of the user.
After first opening (spiking of the infusion port)
The emulsion is to be used immediately after opening of the container.
Storage Do not store above 25 °C.
Do not freeze. If accidentally frozen, discard the bag.
Keep the bag in the protective overwrap in order to protect from light.
Drug group (ATC)? Solutions for parenteral nutrition, combinations
  1. B Blood and blood forming organ drugs
    1. B05 Blood substitutes and perfusion solutions
      1. B05B IV solutions used in parenteral administration of fluids, electrolytes and nutrients
        1. B05BA Solutions for parenteral nutrition
          1. B05BA10 Combination solutions for parenteral nutrition
Marketing authorisation? PL 03551/0144 (first authorised 12 July 2016)
Marketing authorisation holder? B. Braun Melsungen AG

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 11.1.0 of 9 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.